CME: Treatment strategies for hepatocellular carcinoma (HCC): Now, it’s personal(ized)
ACCREDITATION EXPIRED: December 16, 2022
Activity Description / Statement of Need:
In this online, self-learning activity:
Cancer of the liver is one of the leading causes of cancer-related deaths and one of the more common types of cancer worldwide, with an incidence of over 40,000 in the U.S. and an annual mortality rate of over 30,000 new cases each year. Of all the primary liver cancers, hepatocellular carcinoma (HCC) is the most common form, representing 80%, and its incidence has risen threefold in the U.S. over the past 40 years. The largest risk factor is cirrhosis due to chronic hepatitis B or C viruses, and additional risk factors include excess alcohol consumption, diabetes, non-alcoholic fatty liver disease, and smoking. HCC is diagnosed in the intermediate or advanced stages of disease the vast majority of the time and carries a grave prognosis with a five-year survival rate of eighteen percent.
This learning activity has been designed to bring HCPs’ knowledge of optimal, personalized strategies for the management of advanced / unresectable HCC and to improve their competence and performance in treating it.
Target Audience:
The following healthcare professionals: Medical oncologists, hepatologists, physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with advanced / unresectable HCC.
Commercial Support Disclosure: This program is supported by an educational grant from Exelixis.
This activity is free of charge.
Release Date: December 16, 2021 -- Expiration Date: December 16, 2022
Faculty: Josep Llovet, MD
Agenda
|
Faculty introduction, disclosures |
|
|
Introductory content: defining the context and challenge of advanced / unresectable HCC
|
|
|
Treatment of unresectable / advanced HCC
· Child-Turcotte-Pugh class C cirrhosis or extensive comorbidity: Supportive care · Systemic therapy: Present and investigational agents; lines of therapy; efficacy; safety/toxicity and adverse event mitigation; monitoring · VEGF and FGFR inhibition · Checkpoint inhibitor immunotherapy · Tyrosine kinase inhibition · Cytotoxic chemotherapy
|
|
|
Summary, conclusions, and best practice recap |
|
Learning Objectives
By the end of the session the participant will be able to:
- Recall the roles of biomarkers and related testing in personalizing the care plan for patients with unresectable / advanced HCC.
- Summarize the efficacy of existing and anticipated roles of late-stage investigational management strategies in unresectable / advanced HCC treatment algorithms.
- Identify the most clinically relevant adverse events associated with present and emerging unresectable / advanced HCC treatments and recommendations for managing them.
- Formulate a treatment plan for a patient with unresectable / advanced HCC.
Accreditation
ACCME Activity #201805004
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure:
Josep M. Llovet, MD, PhD, FAASLD, Professor of Medicine & Director, Liver Cancer Program. Icahn School of Medicine at Mount Sinai, has received financial compensation for research and/or consulting from: Bayer, Eisai, BMS, Boheringer-Ingelheim, Ipsen, Lilly, Celsion, Exelixis, Merck, Genentech, Roche, Glyotest, Nucleix, Sirtex, Min Alpha, and AstraZeneca.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty will not discuss off-label uses.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Exelixis.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Practice updates in treating advanced-stage gastric and gastroesophageal junction cancers
Biosimilars in the treatment of malignancies and supportive care